Resonant Capital Advisors LLC Purchases 9,762 Shares of Pfizer Inc. (NYSE:PFE)

Resonant Capital Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 11.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 97,898 shares of the biopharmaceutical company’s stock after purchasing an additional 9,762 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Pfizer were worth $2,818,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Davidson Trust Co. raised its position in shares of Pfizer by 5.9% during the 4th quarter. Davidson Trust Co. now owns 14,743 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 815 shares during the last quarter. HTLF Bank bought a new position in Pfizer during the fourth quarter worth about $895,000. Xponance Inc. grew its position in shares of Pfizer by 11.5% during the 4th quarter. Xponance Inc. now owns 891,024 shares of the biopharmaceutical company’s stock worth $25,653,000 after buying an additional 91,843 shares during the period. Integral Investment Advisors Inc. increased its stake in shares of Pfizer by 15.7% in the 4th quarter. Integral Investment Advisors Inc. now owns 19,513 shares of the biopharmaceutical company’s stock valued at $562,000 after acquiring an additional 2,649 shares during the last quarter. Finally, Investors Asset Management of Georgia Inc. GA ADV raised its position in shares of Pfizer by 1.9% in the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 64,890 shares of the biopharmaceutical company’s stock valued at $1,884,000 after acquiring an additional 1,217 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Up 2.2 %

NYSE:PFE traded up $0.57 on Friday, hitting $25.96. 25,890,547 shares of the company’s stock were exchanged, compared to its average volume of 42,249,816. The firm has a 50-day moving average price of $27.14 and a 200-day moving average price of $28.74. Pfizer Inc. has a 52 week low of $25.23 and a 52 week high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market cap of $147.00 billion, a P/E ratio of 71.89, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Pfizer’s revenue was down 41.3% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.